Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
68.39-0.70 (-1.01%)
As of 7:46 AM EDT. Market open.
People also watch:
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open68.75
Prev Close69.09
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range67.54 - 68.77
52wk Range24.83 - 93.82
1y Target EstN/A
Market Cap86.98B
P/E Ratio (ttm)21.27
BetaN/A
Volume1,371,951
Avg Vol (3m)12,151
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Kiplinger2 days ago

    3 Best Dividend Stocks Owned by Warren Buffett

    Berkshire Hathaway has billions invested in Verizon, Sanofi and General Motors.

  • Market Realist2 days ago

    This Changed Sanofi’s Profitability in 2Q16

    Sanofi reported a net profit of ~1.7 billion euros (about $1.9 billion) in 2Q16—a decline of 8.7% in net profits over 2Q15.

  • American City Business Journals2 days ago

    The $150 million winner — and the losers — in Pfizer's $14 billion takeout of Medivation

    Dr. David Hung, who guided cancer drug developer Medivation Inc. through a bidding sweepstakes that culminated in a $14 billion cash offer by Pfizer Inc., could reap change-of-control payouts worth upwards of $150 million. Hung, who founded Medivation (MDVN) a dozen years ago, is one of the big winners in the deal that came to light Sunday . A Medivation spokesperson, it should be noted, said the company would not comment about executive compensation or the math behind it.